SCHEMBL6324016

SCHEMBL6324016

CC(CO)NS(=O)(=O)c1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 3/20 0.53
ALDH1A1 P00352 3/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
CA12 O43570 1/20 0.50
TSHR P16473 1/20 0.50
TDO2 P48775 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.47
IKBKB O14920 2/20 0.45
CHUK O15111 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
ENPP2 Q13822 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
CA1 P00915 1/20 0.41
CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324018 1.00 ADAMTS4 (0.53) ADAMTS4ALDH1A1CA2CA9CA12
SCHEMBL16519484 0.86 CA2 (0.68) ALDH1A1CA2CA9CA12TSHR
SCHEMBL16519485 0.86 CA2 (0.68) ALDH1A1CA2CA9CA12TSHR
SCHEMBL4752500 0.86 CA2 (0.68) ALDH1A1CA2CA9CA12TSHR
SCHEMBL13014153 0.84 ALDH1A1 (0.49) ADAMTS4ALDH1A1CA2CA9CA12
SCHEMBL6321461 0.84 MMP2 (0.56) ALDH1A1CA2CA9CA12TSHR
SCHEMBL6321590 0.84 TDO2 (0.61) ALDH1A1CA2CA9CA12TSHR
SCHEMBL15801255 0.84 NR3C1 (0.51) ADAMTS4ALDH1A1CA2CA9CA12
SCHEMBL13014370 0.84 ALDH1A1 (0.49) ADAMTS4ALDH1A1CA2CA9CA12
SCHEMBL14316552 0.84 NR3C1 (0.51) ADAMTS4ALDH1A1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 ADAMTS4 33/4885ALDH1A1 986/4885CA2 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.